InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

InMode expects Q2 2026 revenue of $95.2M–$95.4M and full-year 2026 revenue of $365M–$375M, pending final results and adjustments. The company also indicated its Special Committee is still evaluating strategic proposals, and it will not hold an investor conference call/webcast for this earnings release.

Analysis

This is less a clean earnings signal than a visibility event. By removing the call while a strategic review is active, management is effectively asking the market to price the company on a thinner information set, which usually widens the discount rate rather than supporting the multiple. For a capital-equipment name tied to discretionary procedure budgets, that increases the risk that customers, distributors, and sales reps pause ordering until they see whether the company is a standalone story or a transaction candidate.

The relative winners are better-diversified med-tech platforms with recurring service or procedure exposure, where any softness in discretionary aesthetics can migrate into a broader quality trade in names like ISRG and SYK. The relative losers are other aesthetic-device vendors and smaller private competitors, because channel hesitation can shift share toward vendors with stronger installed bases, financing support, and service density. If the strategic process drags, INMD’s cash becomes a cushion rather than a catalyst, and buyback support may cap downside without restoring growth credibility.

The contrarian risk is that the market may be overpricing a near-term sale. Strategic reviews in med-tech often stretch for months and can end with no transaction, at which point the stock reverts to fundamentals and lower terminal growth assumptions. The key falsifier is August 5: if management can show sequential booking stability or any improvement in order conversion, the stock can squeeze higher quickly; if not, this looks like a 1-3 month multiple-compression setup rather than a one-day event.

Key Decisions for Investors

• Do not add fresh long INMD exposure into the August 5 print; if already long, hedge 30-50% with short-dated puts or trim into any pre-earnings strength. Risk/reward is asymmetric because the call vacuum reduces upside surprise potential.
• If the stock rallies on takeover speculation before the release, fade it with a 1-3 month short INMD / long ISRG or SYK pair. Thesis: process-risk premium is likely too high versus higher-quality med-tech multiples.
• Set a watch item on August 5 for bookings, sequential demand commentary, and any update on the strategic review. Buy the dip only if management demonstrates stabilization; otherwise treat rallies as exit liquidity.
• For sector exposure, prefer larger diversified med-tech names over discretionary aesthetic-device names until visibility improves. The relative performance gap should widen if channel caution persists for another quarter.